- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3.
Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP – Get Rating) from a buy rating to a hold rating in a research note published on Tuesday, Zacks.com reports. According to Zacks, “GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic […]
GT Biopharma (OTCMKTS:GTBP – Get Rating) announced its quarterly earnings data on Monday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.31), Fidelity Earnings reports. Shares of OTCMKTS:GTBP traded up $0.20 during trading hours on Wednesday, hitting $3.04. The company’s stock had a trading volume of […]
Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment.
Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment.